The journey of gene therapy in haemophilia – putting the patient at the centre of the hub and spoke model

1 Miesbach W, Pasi KJ, Pipe SW, et al. Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre's readiness in United States and EU. Haemophilia 2021; 27(4): 511–514. doi: 10.111/hae.14309. MiesbachW PasiKJ PipeSW Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre's readiness in United States and EU Haemophilia 2021 27 4 511 514 10.111/hae.14309 Open DOISearch in Google Scholar

2 Miesbach W, Chowdary P, Coppens M, et al. Delivery of AAV-based gene therapy through haemophilia centres – A need for re-evaluation of infrastructure and comprehensive care: A joint publication of EAHAD and the EHC. Haemophilia 2021; 27(6): 967–973. doi: 10.1111/hae.14420. MiesbachW ChowdaryP CoppensM Delivery of AAV-based gene therapy through haemophilia centres – A need for re-evaluation of infrastructure and comprehensive care: A joint publication of EAHAD and the EHC Haemophilia 2021 27 6 967 973 10.1111/hae.14420 34553460 Open DOISearch in Google Scholar

3 EUHANET. European guidelines for the certification of haemophilia centres. 2013. Available from http://www.euhanet.org/docs/Euhanet-European_guidelines_for_the_certification_of_Haemophilia_Centres_2013.pdf (accessed 30 August 2022). EUHANET European guidelines for the certification of haemophilia centres 2013 Available from http://www.euhanet.org/docs/Euhanet-European_guidelines_for_the_certification_of_Haemophilia_Centres_2013.pdf (accessed 30 August 2022). Search in Google Scholar

4 Miesbach W, Baghaei F, Boban A, et al. Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and the EHC. Haemophilia 2022; 28: e86–88. doi: 10.1111/hae.14546. MiesbachW BaghaeiF BobanA Gene therapy of hemophilia: Hub centres should be haemophilia centres: A joint publication of EAHAD and the EHC Haemophilia 2022 28 e86 88 10.1111/hae.14546 35263819 Open DOISearch in Google Scholar

5 Miesbach W, Barcenilla SG, Golan G, Lobet S. Implications of haemophilia gene therapy for changing role of the multidisciplinary team. Haemophilia 2022; 28(1): e12–e14. doi: 10.1111/hae.14440. MiesbachW BarcenillaSG GolanG LobetS Implications of haemophilia gene therapy for changing role of the multidisciplinary team Haemophilia 2022 28 1 e12 e14 10.1111/hae.14440 929842934668286 Open DOISearch in Google Scholar

6 Peyvandi F, Lillicrap D, Mahlangu J, et al. Hemophilia gene therapy knowledge and perceptions: Results of an international survey. Res Pract Thromb Haemost 2020; 4(4): 644–651. doi: 10.1002/rth2.12326. PeyvandiF LillicrapD MahlanguJ Hemophilia gene therapy knowledge and perceptions: Results of an international survey Res Pract Thromb Haemost 2020 4 4 644 651 10.1002/rth2.12326 729267332548564 Open DOISearch in Google Scholar

7 Fletcher S, Jenner K, Holland M, Khair K. Expectation and loss when gene therapy for haemophilia is not an option: an Exigency sub-study. 2022 [Manuscript submitted for publication] FletcherS JennerK HollandM KhairK Expectation and loss when gene therapy for haemophilia is not an option: an Exigency sub-study 2022 [Manuscript submitted for publication] Search in Google Scholar

8 Wang M, Negrier C, Driessler F, Goodman C, Skinner ME. The hemophilia gene therapy patient journey: questions and answers for share decision-making. Patient Prefer Adherence 2022; 16: 1439–1447. doi: 10.2147/PPA.S355627. WangM NegrierC DriesslerF GoodmanC SkinnerME The hemophilia gene therapy patient journey: questions and answers for share decision-making Patient Prefer Adherence 2022 16 1439 1447 10.2147/PPA.S355627 919157735707346 Open DOISearch in Google Scholar

9 Fletcher S, Jenner K, Pembroke L, Holland M, Khair K. The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study. Orphanet J Rare Dis 2022; 17: 155. doi: 10.1186/s13023-022-02256-2. FletcherS JennerK PembrokeL HollandM KhairK The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study Orphanet J Rare Dis 2022 17 155 10.1186/s13023-022-02256-2 898174735379267 Open DOISearch in Google Scholar

10 Woollard L, Gorman R, Rosenfelt DJ. Improving patient informed consent for haemophilia gene therapy: the case for change. Ther Adv Rare Dis 2021; 2: 1–16. doi: 10.1177/26330040211047244. WoollardL GormanR RosenfeltDJ Improving patient informed consent for haemophilia gene therapy: the case for change Ther Adv Rare Dis 2021 2 1 16 10.1177/26330040211047244 Open DOISearch in Google Scholar

11 Miesbach W, O'Mahony B, Key NS, Makris M How to discuss gene therapy for haemophilia? A patient and physician perspective. Haemophilia 2019; 25(4): 545–557. doi: 10.1111/hae.13769. MiesbachW O'MahonyB KeyNS MakrisM How to discuss gene therapy for haemophilia? A patient and physician perspective Haemophilia 2019 25 4 545 557 10.1111/hae.13769 685220731115117 Open DOISearch in Google Scholar

12 Kaczmarek R, Pierce GF, Noone D, et al. Eliminating Panglossian thinking in development of AAV therapeutics. Mol Ther 2021; 29(12): 3325–3327. doi: 10.1016/j.ymthe.2021.10.025. KaczmarekR PierceGF NooneD Eliminating Panglossian thinking in development of AAV therapeutics Mol Ther 2021 29 12 3325 3327 10.1016/j.ymthe.2021.10.025 863616634758292 Open DOISearch in Google Scholar

13 Nossair F, Thornburg CD. The role of patient and healthcare professionals in the era of new haemophilia treatments in developed and developing countries. Ther Adv Hematol 2018; 9(8): 239–249. doi: 10.1177/2040620718784830. NossairF ThornburgCD The role of patient and healthcare professionals in the era of new haemophilia treatments in developed and developing countries Ther Adv Hematol 2018 9 8 239 249 10.1177/2040620718784830 611675730181844 Open DOISearch in Google Scholar

14 Konkle BA, Coffin D, Pierce GF, et al. World Federation of Hemophilia Gene Therapy Registry. Haemophilia 2020; 26(4): 563–564. doi: 10.1111/hae.14015. KonkleBA CoffinD PierceGF World Federation of Hemophilia Gene Therapy Registry Haemophilia 2020 26 4 563 564 10.1111/hae.14015 894492232462720 Open DOISearch in Google Scholar

15 Hart DP, Branchford BR, Hendry S, et al. Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study. Orphanet J Rare Dis 2021; 16: 189. doi: 10.1186/s13023-020-01555-w. HartDP BranchfordBR HendryS Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study Orphanet J Rare Dis 2021 16 189 10.1186/s13023-020-01555-w 808283633910590 Open DOISearch in Google Scholar

16 Sidonio RF, Pipe SW, Callaghan MU, Valentino LA, Monahan PE, Croteau SE. Discussing investigational AAV gene therapy with hemophilia patients: A guide. Blood Rev 2021; 47: 100759. doi: 10.1016/j.blre.2020.100759. SidonioRF PipeSW CallaghanMU ValentinoLA MonahanPE CroteauSE Discussing investigational AAV gene therapy with hemophilia patients: A guide Blood Rev 2021 47 100759 10.1016/j.blre.2020.100759 33183859 Open DOISearch in Google Scholar

17 Valentino LA, Blanchette V, Negrier C, et al. Personalising haemophilia management with shared decision making. J Haem Pract 2021; 8(1): 69–79. doi: 10.17225/jhp00178. ValentinoLA BlanchetteV NegrierC Personalising haemophilia management with shared decision making J Haem Pract 2021 8 1 69 79 10.17225/jhp00178 Open DOISearch in Google Scholar

18 Fletcher S, Jenner K, Holland M, Chaplin S, Khair K. An exploration of why men with severe haemophilia might not want gene therapy: The exigency study. Haemophilia 2021; 27(5): 760–768. doi: 10.1111/hae.14378. FletcherS JennerK HollandM ChaplinS KhairK An exploration of why men with severe haemophilia might not want gene therapy: The exigency study Haemophilia 2021 27 5 760 768 10.1111/hae.14378 34265145 Open DOISearch in Google Scholar

19 AHRQ. The SHARE approach: a model for shared decision making. Last reviewed September 2020. Available from https://www.ahrq.gov/health-literacy/professional-training/shared-decision/tools/factsheet.html (accessed 31 August 2022). AHRQ The SHARE approach: a model for shared decision making Last reviewed September 2020. Available from https://www.ahrq.gov/health-literacy/professional-training/shared-decision/tools/factsheet.html (accessed 31 August 2022). Search in Google Scholar

20 Pipe SW, Reddy KJ, Chowdary P. Gene therapy: Practical aspects of implementation. Haemophilia 2022; 28 (Suppl 4): 44–52. doi: 10.1111/hae.14545. PipeSW ReddyKJ ChowdaryP Gene therapy: Practical aspects of implementation Haemophilia 2022 28 Suppl 4 44 52 10.1111/hae.14545 932408935521727 Open DOISearch in Google Scholar

21 Arruda VR, Samelson-Jones BJ. Obstacles and future of gene therapy for hemophilia. Expert Opin Orphan Drugs 2015; 3(9): 997–1010. doi: 10.1517/21678707.2015.1069169. ArrudaVR Samelson-JonesBJ Obstacles and future of gene therapy for hemophilia Expert Opin Orphan Drugs 2015 3 9 997 1010 10.1517/21678707.2015.1069169 Open DOISearch in Google Scholar

22 Leebeek FWG, Miesbach W. Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues. Blood 2021; 138(11): 923–931. doi: 10.1182/blood. LeebeekFWG MiesbachW Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues Blood 2021 138 11 923 931 10.1182/blood Open DOISearch in Google Scholar

23 Miesbach W, Klamroth R. The patient experience of gene therapy for hemophilia: qualitative interviews with trial patients. Patient Prefer Adherence 2020; 14: 767–770. doi: 10.2147/PPA.S239810. MiesbachW KlamrothR The patient experience of gene therapy for hemophilia: qualitative interviews with trial patients Patient Prefer Adherence 2020 14 767 770 10.2147/PPA.S239810 718485832368018 Open DOISearch in Google Scholar

24 Batty P, Lillicrap D. Hemophilia gene therapy: Approaching the first licensed product. Hemasphere 2021; 5(3): e540. doi: 10.1097/HS9.0000000000000540. BattyP LillicrapD Hemophilia gene therapy: Approaching the first licensed product Hemasphere 2021 5 3 e540 10.1097/HS9.0000000000000540 788645833604517 Open DOISearch in Google Scholar

25 Bolz-Johnson M, Meek J, Hoogerbrugge N. “Patient Journeys”: improving care by patient involvement. Eur J Hum Genet 2020; 28: 141–143. doi: 10.1038/s41431-019-0555-6. Bolz-JohnsonM MeekJ HoogerbruggeN “Patient Journeys”: improving care by patient involvement Eur J Hum Genet 2020 28 141 143 10.1038/s41431-019-0555-6 697460031801983 Open DOISearch in Google Scholar